Diammine Dicarboxylic Acid Platinum Enhances Cytotoxicity in Platinum-Resistant Ovarian Cancer Cells through Induction of Apoptosis and S-Phase Cell Arrest

PurposePolysaccharides such as chondroitin play a potent role in tumor growth, tissue repair and angiogenesis. These properties make chondroitin a good candidate for novel drug delivery systems. Diammine dicarboxylic acid platinum (DDAP), a novel polymeric platinum compound, was developed by conjugating the platinum analogue to aspartate–chondroitin for drug delivery to tumor cells. DDAP improves platinum solubility which may reduce systemic toxicity and be more efficacious than cisplatin in killing tumor cells.MethodsWe tested and compared the cytotoxic effects of DDAP and CDDP on the platinum-sensitive 2008 and A2780 ovarian cancer cell lines and their platinum-resistant sublines 2008.C13 and A2780cis; we also investigated DDAP’s mechanism of action.ResultsIn the platinum-sensitive cell lines, the cytotoxic effects of DDAP and CDDP were comparable. However, in the platinum-resistant sublines, significantly greater cell-growth inhibition was induced by DDAP than by CDDP, especially at lower doses. DDAP also induced more apoptosis than CDDP did in the 2008.C13 subline, which was partially mediated by the caspase 3-dependent pathway. In addition, lower (but not higher) doses of DDAP arrested 90% of S-phase 2008.C13 cells, which might be associated with up-regulation of p21 and maintenance of low cyclin A expression. Furthermore, greater cellular uptake of DDAP was seen in platinum-resistant than in platinum-sensitive ovarian cancer cells.ConclusionsLow-dose DDAP enhances drug delivery to platinum-resistant ovarian cancer cells and substantially inhibits their growth by inducting apoptosis and arresting cells in the S-phase, suggesting that DDAP may overcome platinum resistance in ovarian cancer.

[1]  M. Markman,et al.  Primary ovarian cancer chemotherapy: current standards of care , 2003, British Journal of Cancer.

[2]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[3]  V. Sinha,et al.  Polysaccharides in colon-specific drug delivery. , 2001, International journal of pharmaceutics.

[4]  J. Perez,et al.  Novel concepts in the development of platinum antitumor drugs. , 2002, Current medicinal chemistry. Anti-cancer agents.

[5]  S. Fulda,et al.  Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system , 1998, International journal of cancer.

[6]  R. Dashwood,et al.  Caspase-8 and apoptosis-inducing factor mediate a cytochrome c-independent pathway of apoptosis in human colon cancer cells induced by the dietary phytochemical chlorophyllin. , 2003, Cancer research.

[7]  B. Howard,et al.  WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases , 1997, Molecular and cellular biology.

[8]  J. Mano,et al.  Chitosan-Based Particles as Controlled Drug Delivery Systems , 2004, Drug delivery.

[9]  C. Prives,et al.  Decreased p21 Levels Are Required for Efficient Restart of DNA Synthesis after S Phase Block* , 2004, Journal of Biological Chemistry.

[10]  Mcguire Wp,et al.  Chemotherapy of advanced ovarian cancer. , 1998 .

[11]  R. Brown,et al.  Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin. , 1999, Cancer research.

[12]  E. Alnemri,et al.  Abrogation of Mitochondrial Cytochrome c Release and Caspase-3 Activation in Acquired Multidrug Resistance* , 1998, The Journal of Biological Chemistry.

[13]  R. Muzzarelli,et al.  Morphological study of the capsular organization around tissue expanders coated with N-carboxybutyl chitosan. , 1991, Biomaterials.

[14]  C. Rodenburg,et al.  Chemotherapy in advanced ovarian cancer , 2004, Journal of Cancer Research and Clinical Oncology.

[15]  J. Turchi,et al.  Cisplatin-induced Apoptosis Proceeds by Caspase-3-dependent and -independent Pathways in Cisplatin-resistant and -sensitive Human Ovarian Cancer Cell Lines Proteolytic Degradation of Procaspase-3 Was Observed in Both the Cp70 and C30 Cells following Ic 50 Cisplatin Treatment, Whereas No Pro- Teolyze , 2022 .

[16]  R. Schnellmann,et al.  Identification of Caspase-Independent Apoptosis in Epithelial and Cancer Cells , 2004, Journal of Pharmacology and Experimental Therapeutics.

[17]  M. Giraud-Panis,et al.  Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. , 2005, Current medicinal chemistry. Anti-cancer agents.

[18]  M. K. Chourasia,et al.  Polysaccharides for Colon Targeted Drug Delivery , 2004, Drug delivery.

[19]  J. Cummings,et al.  In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer , 2002, British Journal of Cancer.

[20]  J. Thigpen.  Chemotherapy for advanced ovarian cancer: overview of randomized trials. , 2000, Seminars in oncology.

[21]  Robert Brown,et al.  The epigenetics of ovarian cancer drug resistance and resensitization. , 2004, American journal of obstetrics and gynecology.

[22]  A. Jemal,et al.  Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival , 2004, Cancer.

[23]  A. Gartel,et al.  Transcriptional regulation of the p21((WAF1/CIP1)) gene. , 1999, Experimental cell research.

[24]  F. Muggia,et al.  Platinum resistance: Laboratory findings and clinical implications , 1993, Stem cells.

[25]  P. Ravdin.  Overview of randomized trials of systemic adjuvant therapy. , 2000, Cancer treatment and research.

[26]  Robin Shattock,et al.  In Vitro and In Vivo: The Story of Nonoxynol 9 , 2005, Journal of acquired immune deficiency syndromes.

[27]  J. Veerkamp,et al.  Attachment of glycosaminoglycans to collagenous matrices modulates the tissue response in rats. , 2000, Biomaterials.

[28]  B. Howard,et al.  Inhibition of Cyclin-dependent Kinases. Waf1 Retards S-phase Progression Primarily By , 1997 .

[29]  M. Colonna,et al.  NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation , 2002, Nature Immunology.

[30]  E. Papadimitriou,et al.  Characterization of Heparin Affin Regulatory Peptide Signaling in Human Endothelial Cells* , 2005, Journal of Biological Chemistry.

[31]  Ook.,et al.  CYCLOPHOSPHAMIDE AND CISPLATIN COMPARED WITH PACLITAXEL AND CISPLATIN IN PATIENTS WITH STAGE III AND STAGE IV OVARIAN CANCER , 2000 .

[32]  F. Zunino,et al.  Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. , 2003, Current cancer drug targets.

[33]  Jens Pietzsch,et al.  L-Type Amino Acid Transporters LAT1 and LAT4 in Cancer: Uptake of 3-O-Methyl-6- 18F-Fluoro-l-Dopa in Human Adenocarcinoma and Squamous Cell Carcinoma In Vitro and In Vivo , 2007, Journal of Nuclear Medicine.

[34]  M. Piccart,et al.  Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  C. Charnsangavej,et al.  Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  M. McKeage.  New-generation platinum drugs in the treatment of cisplatin-resistant cancers , 2005, Expert opinion on investigational drugs.

[37]  S. Rodenhuis,et al.  Resistance ot cisplatin and analogues: mechanisms and potential clinical implications , 2004, Cancer Chemotherapy and Pharmacology.